UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours

ESMO open, 2020-12, Vol.5 (6), p.e001081, Article e001081

2020

Volltextzugriff (PDF)

Interaction between the Amino- and Carboxyl-terminal Regions of the Rat Androgen Receptor Modulates Transcriptional Activity and Is Influenced by Nuclear Receptor Coactivators

The Journal of biological chemistry, 1997-11, Vol.272 (47), p.29821-29828

1997

Volltextzugriff (PDF)

NMD and microRNA expression profiling of the HPCX1 locus reveal MAGEC1 as a candidate prostate cancer predisposition gene

BMC cancer, 2011-08, Vol.11 (1), p.327-327, Article 327

2011

Volltextzugriff (PDF)

Lactase Persistence, Dietary Intake of Milk, and the Risk for Prostate Cancer in Sweden and Finland

Cancer epidemiology, biomarkers & prevention, 2007-05, Vol.16 (5), p.956-961

2007

Volltextzugriff (PDF)

Real-world assessment of AR-LBD mutations in metastatic castration-resistant prostate cancer

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.204-204

2023

Volltextzugriff (PDF)

Role of the Nijmegen Breakage Syndrome 1 Gene in Familial and Sporadic Prostate Cancer

Cancer epidemiology, biomarkers & prevention, 2006-05, Vol.15 (5), p.935-938

2006

Volltextzugriff (PDF)

Mutual Transcriptional Interference between RelA and Androgen Receptor

The Journal of biological chemistry, 1996-09, Vol.271 (39), p.24151-24156

1996

Volltextzugriff (PDF)

Germ-Line Alterations in MSR1 Gene and Prostate Cancer Risk

Clinical cancer research, 2003-11, Vol.9 (14), p.5252-5256

2003

Volltextzugriff (PDF)

Impact of activating androgen receptor (AR) mutations on AR sensitivity to alternative ligands and response to ODM-208, a selective, first-in-class CYP11A1 inhibitor, in patients with advanced metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.5057-5057

2022

Volltextzugriff (PDF)

MK-5684 (ODM-208), a CYP11A1 inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) with and without AR-LBD mutations: CYPIDES phase 2 results

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.159-159

2024

Volltextzugriff (PDF)

Phase 1 results of the ODM-208 first-in-human phase 1-2 trial in patients with metastatic castration-resistant prostate cancer (CYPIDES)

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.18-18

2022

Volltextzugriff (PDF)

28 Days Without - a new approach to nicotine dependence treatment in Finland

Tobacco prevention & cessation, 2018-06, Vol.4 (Supplement)

2018

Volltextzugriff (PDF)

ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity

Molecular cancer therapeutics, 2019-01, Vol.18 (1), p.28-38

2019

Volltextzugriff (PDF)

Association of E-Cadherin Germ-Line Alterations with Prostate Cancer

Clinical cancer research, 2001-11, Vol.7 (11), p.3465-3471

2001

Volltextzugriff (PDF)

Prevalence and Spectrum of AR Ligand-Binding Domain Mutations Detected in Circulating-Tumor DNA Across Disease States in Men With Metastatic Castration-Resistant Prostate Cancer

JCO precision oncology, 2024-05, Vol.8 (8), p.e2300330

2024

Volltextzugriff (PDF)

Abstract 1753: Targeting cancer with selective cbp/p300 bromodomain inhibitors

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.1753-1753

2020

Volltextzugriff (PDF)

Abstract 4649: ODM-207, a novel BET-bromodomain inhibitor as a therapeutic approach for the treatment of prostate and breast cancer

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.4649-4649

2016

Volltextzugriff (PDF)

Abstract 118: Targeting cancer with a novel BET bromodomain inhibitor ODM-207

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.118-118

2017

Volltextzugriff (PDF)

Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer

NEJM evidence, 2024-01, Vol.3 (1), p.EVIDoa2300171

2024

Volltextzugriff (PDF)

Structure-guided discovery of 1,3,5 tri-substituted benzenes as potent and selective matriptase inhibitors exhibiting in vivo antitumor efficacy

Bioorganic & medicinal chemistry, 2014-06, Vol.22 (12), p.3187-3203

2014

Volltextzugriff (PDF)

Germline Alterations of the RNASEL Gene, a Candidate HPC1 Gene at 1q25, in Patients and Families with Prostate Cancer

American journal of human genetics, 2002-05, Vol.70 (5), p.1299-1304

2002

Volltextzugriff (PDF)

A Combined Genomewide Linkage Scan of 1,233 Families for Prostate Cancer–Susceptibility Genes Conducted by the International Consortium for Prostate Cancer Genetics

American journal of human genetics, 2005-08, Vol.77 (2), p.219-229

2005

Volltextzugriff (PDF)

Profiling genetic variation along the androgen biosynthesis and metabolism pathways implicates several single nucleotide polymorphisms and their combinations as prostate cancer risk factors

Cancer research (Chicago, Ill.), 2006-01, Vol.66 (2), p.743-747

2006

Volltextzugriff (PDF)

Pooled genome linkage scan of aggressive prostate cancer : results from the International Consortium for Prostate Cancer Genetics

Human genetics, 2006-11, Vol.120 (4), p.471-485

SCHAID, Daniel J

2006

Volltextzugriff (PDF)

ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer

Cancer research (Chicago, Ill.), 2001-08, Vol.61 (16), p.6038-6041

2001

Volltextzugriff (PDF)

1 – 25 von 67

Suche als RSS-Feed

Aktive Filter

SpracheEnglisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(65)
Mit Volltextzugriff
(56)

Publikationsform

Artikel
(67)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours

Interaction between the Amino- and Carboxyl-terminal Regions of the Rat Androgen Receptor Modulates Transcriptional Activity and Is Influenced by Nuclear Receptor Coactivators

NMD and microRNA expression profiling of the HPCX1 locus reveal MAGEC1 as a candidate prostate cancer predisposition gene

Lactase Persistence, Dietary Intake of Milk, and the Risk for Prostate Cancer in Sweden and Finland

Real-world assessment of AR-LBD mutations in metastatic castration-resistant prostate cancer

Role of the Nijmegen Breakage Syndrome 1 Gene in Familial and Sporadic Prostate Cancer

Mutual Transcriptional Interference between RelA and Androgen Receptor

Germ-Line Alterations in MSR1 Gene and Prostate Cancer Risk

Impact of activating androgen receptor (AR) mutations on AR sensitivity to alternative ligands and response to ODM-208, a selective, first-in-class CYP11A1 inhibitor, in patients with advanced metastatic castration-resistant prostate cancer (mCRPC)

MK-5684 (ODM-208), a CYP11A1 inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) with and without AR-LBD mutations: CYPIDES phase 2 results

Phase 1 results of the ODM-208 first-in-human phase 1-2 trial in patients with metastatic castration-resistant prostate cancer (CYPIDES)

28 Days Without - a new approach to nicotine dependence treatment in Finland

ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity

Association of E-Cadherin Germ-Line Alterations with Prostate Cancer

Prevalence and Spectrum of AR Ligand-Binding Domain Mutations Detected in Circulating-Tumor DNA Across Disease States in Men With Metastatic Castration-Resistant Prostate Cancer

Abstract 1753: Targeting cancer with selective cbp/p300 bromodomain inhibitors

Abstract 4649: ODM-207, a novel BET-bromodomain inhibitor as a therapeutic approach for the treatment of prostate and breast cancer

Abstract 118: Targeting cancer with a novel BET bromodomain inhibitor ODM-207

Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer

Structure-guided discovery of 1,3,5 tri-substituted benzenes as potent and selective matriptase inhibitors exhibiting in vivo antitumor efficacy

Germline Alterations of the RNASEL Gene, a Candidate HPC1 Gene at 1q25, in Patients and Families with Prostate Cancer

A Combined Genomewide Linkage Scan of 1,233 Families for Prostate Cancer–Susceptibility Genes Conducted by the International Consortium for Prostate Cancer Genetics

Profiling genetic variation along the androgen biosynthesis and metabolism pathways implicates several single nucleotide polymorphisms and their combinations as prostate cancer risk factors

Pooled genome linkage scan of aggressive prostate cancer : results from the International Consortium for Prostate Cancer Genetics

ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer

Aktive Filter

Suchergebnisse filtern